Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
-2°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Personalis Inc
(NQ:
PSNL
)
3.970
+0.040 (+1.02%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Personalis Inc
< Previous
1
2
3
4
5
Next >
Personalis to Participate at Upcoming Investor Conferences
November 20, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the Stifel 2024 Healthcare Conference
November 05, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Third Quarter 2024 Financial Results
October 23, 2024
From
Personalis, Inc.
Via
Business Wire
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
September 16, 2024
From
Personalis, Inc.
Via
Business Wire
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
August 23, 2024
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Personalis to Participate at Upcoming Investor Conferences
August 22, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and Tempus Announce Expanded Collaboration
August 16, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Personalis, Inc.
Via
Business Wire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
July 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Second Quarter 2024 Financial Results
July 24, 2024
From
Personalis, Inc.
Via
Business Wire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
June 18, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
June 13, 2024
From
Personalis, Inc.
Via
Business Wire
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
June 04, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
May 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
May 22, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports First Quarter 2024 Financial Results
May 08, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
March 26, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at Upcoming Investor Conferences
January 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
January 30, 2024
From
Personalis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
